secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2021-08-26T23:59:59+00:00
Accession:  0001171843-21-006167
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst appoints former FDA CDER director Steven Galson to board of directors
------------------------------------------------------------------------------

- Board expanded from 9 to 10; Galson effective Sept 1, 2021, term ends at 2022 annual meeting.
- Galson is former FDA CDER director, acting U.S. surgeon general, and ex-SVP R&D at Amgen.
- Receives automatic grant of 60,000 stock options upon joining, plus 40,000 annually subject to tenure.
- Appointed to Science Committee; compensation per company's director compensation policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184321006167/0001171843-21-006167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184321006167/f8k_082621.htm
  HTML page:      https://secwatch.observer/filing/0001171843-21-006167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer